[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646411":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":51,"collaborators":11,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":11,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":11,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"hUCMSC-Exosome Injection","EXPERIMENTAL",null,[13],"Drug: Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes",{"label":15,"type":16,"description":11,"interventionNames":17},"Normal Saline Injection","PLACEBO_COMPARATOR",[18],"Other: Normal Saline (0.9% NaCl)",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes","Sterile exosome suspension derived from human umbilical cord mesenchymal stem cells (hUCMSC-Exos). Administered via intradermal scalp injection at 0.05 mL per point, 1 cm spacing, approximately 4 mm depth. Treatment repeated once every 4 weeks for a total of 3 sessions.",[9],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Normal Saline (0.9% NaCl)","Sterile 0.9% normal saline injection. Administered via intradermal scalp injection using the same protocol as the experimental group: 0.05 mL per point, 1 cm spacing, approximately 4 mm depth, once every 4 weeks for a total of 3 sessions.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Han Zhang","CONTACT","18510009269","zhang_han_0112@163.com",[36],{"facility":37,"status":38,"city":39,"state":11,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"No.28 Fuxing Road","RECRUITING","Beijing","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49],{"name":50,"role":32,"phone":33,"phoneExt":11,"email":34},"han Zhang",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Zhang Han","Associate Chief Physician","100646411","phase-2-exosome-therapy-for-male-androgenetic-alopecia-100646411",false,"NCT07693244","Exosome Therapy for Male Androgenetic Alopecia","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Efficacy and Safety of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Male Androgenetic Alopecia","Inclusion Criteria\n\nParticipants must meet all of the following criteria to be eligible for enrollment:\n\n1. Male subjects aged 18 to 55 years;\n2. Diagnosis of androgenetic alopecia classified as Norwood-Hamilton grade III-V;\n3. Stable pattern of hair loss for at least 6 months prior to screening;\n4. Willingness to refrain from using any other hair loss treatments during the study period and for 6 months after completion of treatment.\n\nExclusion Criteria\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. Other types of alopecia, including alopecia areata, cicatricial alopecia, or telogen effluvium;\n2. Use of minoxidil, finasteride, spironolactone, or other hair growth-related medications within 1 year prior to screening;\n3. Receipt of platelet-rich plasma (PRP), laser cap therapy, or other scalp procedures within 6 months prior to screening;\n4. History of autoimmune disease, active scalp infection, coagulation disorders, or malignancy;\n5. Known hypersensitivity to the investigational product or any of its components;\n6. Inability to comply with study procedures, incomplete clinical data, or conditions that may interfere with efficacy evaluation;\n7. Participation in another clinical trial within the study period;\n8. Any condition that, in the opinion of the investigator, makes the participant unsuitable for the study.","MALE","18 Years","55 Years",{"count":66,"type":67},120,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","The goal of this clinical trial is to learn if local scalp injection of human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) can treat androgenetic alopecia (AGA) in male patients with AGA.\n\nThe main question it aims to answer is:\n\nDoes hUCMSC-Exos injection improve hair regrowth compared with placebo?\n\nResearchers will compare hUCMSC-Exos injection to placebo injection to see if hUCMSC-Exos leads to superior efficacy in hair follicle regeneration, as measured by changes in hair density, hair thickness, and patient-reported outcomes.\n\nParticipants will:\n\nReceive randomized, double-blinded local scalp injections of either hUCMSC-Exos or placebo\n\nAttend scheduled follow-up visits for hair assessment and safety monitoring\n\nUndergo photography, trichoscopy, and complete quality-of-life or psychosocial burden questionnaires as applicable",[73],"Androgenetic Alopecia (AGA)",[75,76,77,78,79],"Androgenetic Alopecia","Exosomes","hUCMSC-Exos","Mesenchymal Stem Cells","Randomized Controlled Trial","2026-07-06",{"date":82,"type":83},"2026-07-09","ACTUAL",{"date":85,"type":83},"2026-04-30",{"date":87,"type":67},"2026-11-10",{"name":53,"class":6},1]